ClinicalTrials.gov
public full text
Public Domain
Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD
The objective of this study is to identification of neuropsychological, genetic and neuroimaging markers and treatment response predictors of attention-deficit/hyperactivity disorder (ADHD). Participants who take the standardized pharmacotherapy (methylphenidate or atomoxetine) for ADHD will be observed for 52 weeks. They will do several neuropsychological, neuroimaging and genetic tests at visit 1\~6.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)#913429
- Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD#1307130
- QbTest Utility for Optimising Treatment in ADHD (QUOTA)#861594
- Dietary Intake and Nutrient Status of Children With ADHD#853520
- Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD#1115292
Record · ID 1431002
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive